Journal article
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
- Abstract:
-
Background Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocorticoids among these patients was responsible for this finding, and tested if inhaled glucocorticoids would be an effective treatment for early COVID-19.
Methods We performed an open-label, parallel-group...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, 797.0KB)
-
(Supplementary materials, 1.7MB)
-
- Publisher copy:
- 10.1016/S2213-2600(21)00160-0
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Respiratory Medicine Journal website
- Volume:
- 9
- Issue:
- 7
- Pages:
- 763-772
- Publication date:
- 2021-04-09
- Acceptance date:
- 2021-03-19
- DOI:
- ISSN:
-
2213-2600
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1170382
- Local pid:
- pubs:1170382
- Deposit date:
- 2021-04-03
Terms of use
- Copyright holder:
- Elsevier Ltd.
- Copyright date:
- 2021
- Rights statement:
- © 2021 Elsevier Ltd.
- Notes:
-
This is the accepted manuscript version of the article. The final version is available from Elsevier at https://doi.org/10.1016/S2213-2600(21)00160-0
If you are the owner of this record, you can report an update to it here: Report update to this record